# Huayuan Zhiyin (Beijing) Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huayuan-zhiyin-beijing-biotechnology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Latest round: Seed (Jul 7, 2026)
- Investors on record: 1

## About

Based in Beijing, China and founded in 2025, Huayuan Zhiyin (Beijing) Biotechnology Co., Ltd. is an AI life science company dedicated to building large-scale "virtual cell" models that integrate multi-omics, biological pathways, and cell interaction information to simulate and predict cell behavior and drive innovation in precision medicine and drug development. In July 2026, Huayuan Zhiyin (Beijing) Biotechnology Co., Ltd. raised a seed funding led by Tsinghua Innovation Ventures.

The company provides services based on virtual cell models for drug efficacy prediction, patient stratification, clinical trial optimization, and personalized treatment plan prediction. It continuously trains models using real-world clinical data to assist hospitals and pharmaceutical companies in decision-making.

The company's revenue is generated by providing services based on virtual cell models for drug efficacy prediction, patient stratification, clinical trial optimization, and personalized treatment plan prediction. It continuously trains models using real-world clinical data to assist hospitals and pharmaceutical companies in decision-making.

The company will use the funding for iterating on multimodal sequencing underlying technology, further expanding cooperation with leading tertiary hospitals, and team expansion.

## Funding rounds

- Seed, Jul 7, 2026 — Tsinghua Innovation Ventures

## Investors

- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Seed